Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Robert J. Motzer, Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R. Plimack, Philippe Barthélémy, Hans J. Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K. Choueiri, Brian I. Rini, Pamela Salman, Christian K. Kollmannsberger, Scott S. TykodiMarc Oliver Grimm, Howard Gurney, Raya Leibowitz-Amit, Poul F. Geertsen, Asim Amin, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences